HC Wainwright Forecasts Armata Pharmaceuticals Q3 Earnings

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) – Equities researchers at HC Wainwright decreased their Q3 2026 earnings per share estimates for shares of Armata Pharmaceuticals in a report released on Thursday, August 13th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($0.57) per share for the quarter, down from their previous forecast of ($0.53). The consensus estimate for Armata Pharmaceuticals’ current full-year earnings is $0.50 per share. HC Wainwright also issued estimates for Armata Pharmaceuticals’ Q4 2026 earnings at ($0.57) EPS, FY2026 earnings at $0.50 EPS and FY2027 earnings at ($2.04) EPS.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.17. The company had revenue of $2.51 million for the quarter, compared to the consensus estimate of $0.40 million. Armata Pharmaceuticals had a negative net margin of 3,467.04% and a negative return on equity of 12.24%.

Separately, Zacks Research upgraded shares of Armata Pharmaceuticals to a “hold” rating in a report on Monday, May 18th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $15.00.

Armata Pharmaceuticals Stock Performance

Shares of Armata Pharmaceuticals stock opened at $4.56 on Monday. The stock has a market capitalization of $167.40 million, a PE ratio of -0.60 and a beta of 1.30. Armata Pharmaceuticals has a 52-week low of $2.40 and a 52-week high of $16.34. The company has a 50-day simple moving average of $5.46 and a two-hundred day simple moving average of $8.09.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Madison Asset Management LLC purchased a new stake in shares of Armata Pharmaceuticals during the first quarter valued at $21,583,000. 683 Capital Management LLC purchased a new position in Armata Pharmaceuticals in the 4th quarter worth about $878,000. Bank of New York Mellon Corp purchased a new position in Armata Pharmaceuticals in the 2nd quarter worth about $193,000. Bank of America Corp DE raised its position in Armata Pharmaceuticals by 233.2% in the 1st quarter. Bank of America Corp DE now owns 11,714 shares of the company’s stock worth $120,000 after buying an additional 8,198 shares during the last quarter. Finally, Millennium Management LLC bought a new position in Armata Pharmaceuticals during the 4th quarter valued at about $164,000. Hedge funds and other institutional investors own 3.57% of the company’s stock.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.